Novartis Ag (NVSEF) Short term Debt (2009 - 2025)

Novartis Ag has disclosed Short term Debt across 12 years of filings, most recently posting $794.0 million for Q4 2025.

• Short term Debt for Q4 2025 came in at $794.0 million, up 23.68% year-over-year; the trailing twelve-month figure through Dec 2025 was $794.0 million (up 23.68% YoY), and the FY2025 annual result was $794.0 million, up 23.68% from the prior year.
• Short term Debt came in at $794.0 million for Q4 2025 at Novartis Ag, down from $8.3 billion in the prior quarter.
• In the past five years, Short term Debt ranged from a high of $9.1 billion in Q2 2021 to a low of $624.0 million in Q4 2023.
• The 5-year median for Short term Debt is $6.7 billion (2021), against an average of $5.5 billion.
• Across the five-year window, Short term Debt surged 177.07% in 2021 and sank 89.48% in 2023, its largest moves.
• Novartis Ag's Short term Debt stood at $6.3 billion in 2021, then retreated by 5.78% to $5.9 billion in 2022, then tumbled by 89.48% to $624.0 million in 2023, then rose by 2.88% to $642.0 million in 2024, then grew by 23.68% to $794.0 million in 2025.
• The last three Short term Debt figures came in at $794.0 million (Q4 2025), $8.3 billion (Q2 2025), and $642.0 million (Q4 2024), per Business Quant data.